Cancer anorexia-cachexia syndrome: Current issues in research and management

Ca-A Cancer Journal for Clinicians

Volumn 52, Issue 2, 2002, Pages 72-91

  Inui, Akio ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APPETITE STIMULANT; BRANCHED CHAIN AMINO ACID; CANNABINOID DERIVATIVE; CISPLATIN; CORTICOSTEROID DERIVATIVE; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; GAMMA INTERFERON; GESTAGEN; GLUCOCORTICOID; HISTAMINE H2 RECEPTOR ANTAGONIST; ICOSAPENTAENOIC ACID; INTERLEUKIN 1; INTERLEUKIN 6; LIPID; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MELATONIN; METHOTREXATE; METHYLPREDNISOLONE; OPIATE; PREDNISOLONE; PROKINETIC AGENT; SEROTONIN ANTAGONIST; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ADIPOSE TISSUE; AGED; ANOREXIA; ARTICLE; CACHEXIA; CHILD; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DELIRIUM; DIET THERAPY; DISTRESS SYNDROME; DOSE RESPONSE; DRUG COST; DRUG FORMULATION; DRUG MECHANISM; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; INHIBITION KINETICS; METABOLIC DISORDER; MOUSE; MUSCLE TISSUE; NONHUMAN; PATHOGENESIS; PEPTIC ULCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; QUALITY OF LIFE; RAT; UTERUS BLEEDING; WASTING SYNDROME; WEIGHT REDUCTION;

EID: 0036198117     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.52.2.72     Document Type: Article

References (154)

1. Biology of cachexia
2. Anorexia, cachexia and nutrition
3. Thwarting the dwindling progression of cachexia
4. Cancer anorexia-cachexia syndrome: Are neuropeptides the key?
5. Cachexia
6. Cancer cachexia
7. Cachexia and anorexia: Cancer's covert killer
8. The pathophysiology of cachexia in advanced cancer and AIDS
9. Pancreatic cancer as a model: Inflammatory mediators, acute-phase response, and cancer cachexia
10. Practical concepts for clinicians
11. The assessment of the nutritional status, caloric intake, and appetite of patients with advanced cancer
12. Time-dependent variation in weight and body composition in healthy adults
13. The Body Cell Mass and Its Supporting Environment
14. Prognostic effect of weight loss prior to chemotherapy in cancer patients
15. Analysis of the energy balance in lung cancer patients
16. Contribution of anorexia and hypermetabolism to weight loss in anicteric patients with pancreatic cancer
17. Clinical review 94: What's in a name? In search of leptin's physiologic role
18. Hypothalamic response to starvation: Implications for the study of wasting disorders
19. Neuroendocrine responses to starvation and weight loss
20. Feeding and body-weight regulation by hypothalamic neuropeptides-mediation of the actions of leptin
21. Leptin and the regulation of body weight in mammals
22. Unraveling the central nervous system pathways underlying responses to leptin
23. Signals that regulate food intake and energy homeostasis
24. The MONA LISA hypothesis in the time of leptin
25. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight
26. Central nervous system control of food intake
27. Transgenic approach to the study of body weight regulation
28. Transgenic study of energy homeostasis equation: Implications and confounding influences
29. 3rd Proinflammatory cytokines, nutritional support, and the cachexia syndrome: Interactions and therapeutic options
30. Anticytokine approaches to the treatment of anorexia and cachexia
31. Cytokine activity in cancer-related anorexia/cachexia: Role of megestrol acetate and medroxyprogesterone acetate
32. Neuropeptide Y: A key molecule in anorexia and cachexia in wasting disorders?
33. Cachexia-anorexia workshop: Introduction
34. Central nervous system mechanisms contributing to the cachexia-anorexia syndrome
35. Metabolic abnormalities in cachexia and anorexia
36. Regulation of skeletal-muscle-protein turnover in cancer-associated cachexia
37. Workshop summary and conclusions
38. The role of cytokines in cancer cachexia
39. Are cytokines possible mediators of cancer cachexia?
40. Cytokines and cachexia
41. Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia
42. Assessment of feeding response of tumor-bearing rats to hypothalamic injection and infusion of neuropeptide Y
43. Hypothalamic concentration and release of neuropeptide Y into microdialysates is reduced in anorectic tumor-bearing rats
44. Alterations in hypothalamic NPY and CRF in anorexic tumor-bearing rats
45. Neuropeptide Y blocks and reverses interleukin-1β-induced anorexia in rats
46. Central nervous system IL-1β system and neuropeptide Y mRNA during IL-1β-induced anorexia in rats
47. Anorexia induced by cytokine interactions at pathophysiological concentrations
48. Transplantable rat glucagonomas cause acute onset of severe anorexia and adipsia despite highly elevated NPY mRNA levels in the hypothalamic arcuate nucleus
49. Brain cytokine mRNAs in anorectic rats bearing prostate adenocarcinoma tumor cells
50. Role of the central melanocortin system in cachexia
51. Reversal of Cancer anorexia by blockade of central melanocortin receptors in rats
52. Hypothalamic melanocortin signaling in cachexia
53. The cancer anorexia-cachexia syndrome
54. Fatigue and cachexia in cancer patients. Support
55. Recently identified peptides involved in the regulation of body weight
56. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer
57. Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients
58. Cancer anorexia and cachexia
59. Protein-calorie undernutrition in hospitalized cancer patients
60. Skeletal muscle metabolism in patients with malignant tumor
61. Cancer cachexia and protein metabolism
62. Acute-phase protein response and survival duration of patients with pancreatic cancer
63. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients
64. Serum level of interleukin-6 as a prognostic factor in metastatic renal cell carcinoma
65. Do the differences between the amino acid compositions of acute-phase and muscle proteins have a bearing on nitrogen loss in traumatic states?
66. Bioactivity of skeletal muscle proteolysis-inducing factors in the plasma proteins from cancer patients with weight loss
67. Increased protein degradation and decreased protein synthesis in skeletal muscle during cancer cachexia
68. Characterization of a cancer cachectic factor
69. Protein loss in cancer cachexia
70. NF-κB-induced loss of MyoD messenger RNA: Possible role in muscle decay and cachexia
71. Nutritional support of the cancer patient: Issues and dilemmas
72. Anorexia as a general effect of cancer
73. Abnormalities of taste sensation in cancer patients
74. Learned taste aversions in children receiving chemotherapy
75. Opioids and food intake: Distributed functional neural pathways?
76. Peptidergic regulation of gastrointestinal motility in rodents
77. Central nervous system action of peptides to influence gastrointestinal motor function
78. Delayed gastric emptying in bulimic patients
79. EM523L, a nonpeptide motilin agonist, stimulates gastric emptying and pancreatic polypeptide secretion
80. Gastrointestinal toxicity of chemotherapeutic agents
81. Metabolic sequelae of cancers (excluding bone marrow transplantation)
82. The syndrome of anorexia-cachexia
83. Nutrition support in clinical practice: Review of published data and recommendations for future research directions
84. Role of nutrition support during induction chemoradiation therapy in esophageal cancer
85. Can reducing caloric intake also help reduce cancer?
86. The cancer anorexia-cachexia syndrome
87. A review of the drug treatment of cachexia associated with cancer
88. Cancer cachexia: A therapeutic approach
89. Pharmacological treatment of cachexia: Any progress?
90. Pharmacological approach to cancer anorexia and cachexia
91. Managing cancer-related anorexia / cachexia
92. Corticosteroid therapy of preterminal gastrointestinal cancer
93. Action of oral methylprednisolone in terminal cancer patients: A prospective randomized double-blind study
94. Methylprednisolone as palliative therapy for female terminal cancer patients
95. Prednisolone as an appetite stimulant in patients with cancer
96. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia
97. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia
98. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer
99. Treatment of cancer anorexia with megestrol acetate: Which is the optimal dose?
100. Megestrol acetate in cancer anorexia and weight loss
101. Body-composition changes in patients who gain weight while receiving megestrol acetate
102. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: A North Central Cancer Treatment Group study
103. Pharmacologic management of anorexia/cachexia
104. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: A systemic review of randomized clinical trials
105. Megestrol acetate stimulates food intake in the rat: Effects on regional hypothalamic neuropeptide Y concentrations
106. Residual Ca2+ channel current modulation by megestrol acetate via a G-protein alpha s-subunit in rat hypothalamic neurons
107. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia
108. Hypothalamic dopamine and serotonin in the regulation of food intake
109. Cracking the riddle of cancer anorexia
110. A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome
111. Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome
112. Improved protein kinetics and albumin synthesis by branched chain amino acid-enriched total parenteral nutrition in cancer cachexia. A prospective randomized crossover trial
113. Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients
114. Chronic nausea
115. Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer
116. Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover
117. Inhibition of lipolysis and muscle protein degradation by EPA in cancer cachexia
118. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer
119. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6
120. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer
121. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: A randomized control trial
122. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia
123. Recent clinical experience with dronabinol
124. Leptin-regulated endocannabinoids are involved in maintaining food intake
125. Anticachectic activity of 5′-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma
126. Effect of a fluorinated pyrimidine on cachexia and tumor growth in murine cachexia models: Relationship with a proteolysis inducing factor
127. Anti-cancer drugs affect cancer anorexia and cachexia
128. Is there a role for melatonin in the treatment of neoplastic cachexia?
129. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung poor clinical state
130. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection
131. Thalidomide in patients with cachexia due to terminal cancer: Preliminary report
132. Thalidomide is an inhibitor of angiogenesis
133. Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway
134. Clenbuterol, a beta-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients
135. Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients
136. Effect of ibuprofen on the acute-phase response and protein metabolism in patients with cancer and weight loss
137. Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients
138. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss
139. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors
140. Cytokine and sickness behavior: Implications from knockout animal models
141. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
142. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial
143. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer
144. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer
145. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: A randomized placebo-controlled, double-blind phase III study of the cancer and leukemia Group B
146. Influence of nadrolone decanoate on weight loss in advanced non-small cell lung cancer
147. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia
148. The starving patient: Supportive care for people with cancer
149. Anorexia-cachexia syndrome
150. Psychological impact of cancer cachexia on the patient and family
151. Role of leptin in the neuroendocrine response to fasting
152. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin
153. An orexigenic and somatotrophic signal from the stomach
154. Cancer anorexia/cachexia